Document is current
Any future updates will be listed below
-
Authors
Kraehenbuehl, Lukas https://orcid.org/0000-0001-5411-5661
Weng, Chien-Huan https://orcid.org/0000-0002-5478-9188
Eghbali, Shabnam https://orcid.org/0000-0002-1326-0050
Wolchok, Jedd D. https://orcid.org/0000-0001-6718-2222
Merghoub, Taha https://orcid.org/0000-0002-1518-5111
- License Information
-
More Information
Article History
Accepted: 13 August 2021
First Online: 27 September 2021
Competing interests
: S.E. has acted as a consultant for Cabaletta Bio. J.D.W. has acted as a consultant for Adaptive Biotech, Amgen, Apricity, Arsenal IO, Ascentage Pharma, Astellas, AstraZeneca, Bayer, Beigene, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Daiichi Sankyo, Dragonfly, Eli Lilly, Elucida, F Star, Georgiamune, Idera, Imvaq, Kyowa Hakko Kirin, Linneaus, Maverick Therapeutics, Merck, Neon Therapeutics, Polynoma, Psioxus, Recepta, Sellas, Serametrix, Surface Oncology, Syndax, Syntalogic, Takara Bio, Trieza, Truvax, Trishula and Werewolf Therapeutics, has received research funding from Bristol Myers Squibb and Sephora, holds equity in Adaptive Biotechnologies, Apricity, Arsenal IO, Beigene, Georgiamune, Imvaq, Linneaus and Tizona Pharmaceuticals, and is listed as a co-inventor on patents relating to the use of anti-CD40 agonistic monoclonal antibodies fused with monophosphoryl lipid A (MPL) for cancer therapy, alphavirus replicon particles expressing TRP2, anti-PD-1 antibodies, anti-CTLA4 antibodies, anti-GITR antibodies and methods of use thereof, CAR T cells targeting differentiation antigens as a means to treat cancer, engineered vaccinia viruses for cancer immunotherapy, identifying and treating patients at risk of checkpoint blockade-associated colitis, genomic signatures to identify responders to ipilimumab in melanoma, immunosuppressive follicular helper-like T cells modulated by immune-checkpoint blockade and phosphatidylserine-targeting agents and uses thereof for adoptive T cell therapies, myeloid-derived suppressor cell (MDSC) assays, Newcastle Disease viruses for cancer therapy, and xenogeneic DNA vaccines. T.M. has acted as a consultant for Immunogenesis, Immunos Therapeutics and Pfizer, has received research support from Adaptive Biotechnologies, Aprea, Bristol Myers Squibb, Infinity Pharmaceuticals, Kyn Therapeutics, Leap Therapeutics, Peregrine Pharmaceuticals and Surface Oncology, is listed as a co-inventor on patents relating to the use of oncolytic viral therapy, alphavirus-based vaccines, antibodies targeting CD40, GITR, OX40, PD-1 and CTLA-4 and neo-antigen modelling, and is a cofounder of and holds an equity in IMVAQ Therapeutics. L.K. and C.-H.W. declare no competing interests.
